Anti-atherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase independent mechanisms.

@article{Koshibu2019AntiatherogenicEO,
  title={Anti-atherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase independent mechanisms.},
  author={Masakazu Koshibu and Yusaku Mori and Tomomi C. Saito and Hideki Kushima and Munenori Hiromura and Michishige Terasaki and Michiya Takada and Tomoyasu Fukui and Tsutomu Hirano},
  journal={American journal of physiology. Endocrinology and metabolism},
  year={2019}
}
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert potent glucose lowering effects without increasing risks for hypoglycemia and weight gain. Preclinical studies have demonstrated direct anti-atherogenic effects of GLP-1RAs in normoglycemic animal models; however, the underlying mechanisms in hyperglycemic conditions have not been fully clarified. Here, we aimed to elucidate the role of AMP-activated protein kinase (AMPK) in anti-atherogenic effects of GLP-1RAs in hyperglycemic mice… CONTINUE READING
BETA
1
Twitter Mention